FDA Approves VAFSEO — Akebia Therapeutics, Inc.

# FDA Approves Akebia Therapeutics' VAFSEO for Anemia Treatment The FDA has approved Akebia Therapeutics' VAFSEO (vadadustat), an oral hypoxia-inducible factor (HIF) stabilizer, positioning the company to compete in the competitive anemia market dominated by existing erythropoiesis-stimulating agents. The approval marks a significant milestone for Akebia and expands treatment options for patients with anemia associated with chronic kidney disease.